KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Payables (2018 - 2025)

BioNTech SE's Payables history spans 8 years, with the latest figure at $622.6 million for Q4 2025.

  • On a quarterly basis, Payables rose 36.55% to $622.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $622.6 million, a 36.55% increase, with the full-year FY2025 number at $604.3 million, up 32.54% from a year prior.
  • Payables hit $622.6 million in Q4 2025 for BioNTech SE, up from $512.4 million in the prior quarter.
  • Over the last five years, Payables for BNTX hit a ceiling of $949.3 million in Q2 2024 and a floor of $34.3 million in Q1 2023.
  • Historically, Payables has averaged $422.6 million across 5 years, with a median of $383.4 million in 2023.
  • Biggest five-year swings in Payables: tumbled 89.04% in 2023 and later surged 852.35% in 2024.
  • Tracing BNTX's Payables over 5 years: stood at $206.1 million in 2021, then grew by 2.05% to $210.4 million in 2022, then skyrocketed by 82.23% to $383.4 million in 2023, then increased by 18.94% to $456.0 million in 2024, then surged by 36.55% to $622.6 million in 2025.
  • Business Quant data shows Payables for BNTX at $622.6 million in Q4 2025, $512.4 million in Q3 2025, and $615.4 million in Q2 2025.